The full scientific programme for the 2026 ‘From Insight to Decision’ e-symposium, which is taking place on 2 and 8 December, has been announced by CN Bio. The event will feature expert-led sessions offering practical, real-world guidance on organ-on-a-chip (OOC) use within existing R&D strategies. Launched in… Read More
The pharmacological behaviour of drugs is determined not only by their intrinsic properties but also by the sensitivity of the biological systems in which they are evaluated. Variations in receptor density and signal transduction efficiency can significantly influence observed drug responses, complicating the translation of in vitro findings to in… Read More
Scientists have successfully used a drug to prolong the lifespan of several species of animals, in some cases by more than 25%. The study, published in Aging Cell, found strong evidence that triggering a protein, governing energy levels, may help organisms live significantly longer. … Read More
The global informatics market is expected to triple in size in the next ten years. These technologies are speeding up the process of drug development, but also enabling better accuracy, more precision, more reproducibility and ultimately, better science. This eBook explores the latest developments in artificial… Read More
Atrogi has revealed positive data from a human trial for its lead candidate ATR-258, a first-in-class small molecule oral GRK2-biased β2-adrenergic modulator. ATR-258 is designed to target skeletal muscle through a novel GRK2-biased signalling mechanism, with the goal of improving body composition by reducing fat mass while… Read More
Nuclera has appointed Carl Raimond as Chief Executive Officer, effective immediately. Dr Michael Chen, Nuclera’s Co-founder and former CEO, transitions to the role of Chief Scientific and Business Officer, continuing to provide scientific leadership while supporting market development and strategic partnerships. The leadership transition reportedly marks the… Read More
SciBrunch Therapeutics and MSD (or Merck & Co) have entered into an exclusive global license agreement for SPR2015, an investigational preclinical oral KRAS G12D (ON) inhibitor. Under the agreement, SciBrunch has granted MSD exclusive rights to develop, manufacture and commercialise SPR2015 worldwide. SciBrunch will receive… Read More
Hosted by Drug Discovery World and supported by Bio-Techne this webinar will explore the advances and challenges taking place within the cell and gene therapy field. You will hear from Hans Schambye CEO at BOOST Pharma, Lucas Arruda, CSO at CuraCell, and Brandon Cieniewicz, Director, Research & Development at CERo… Read More
Researchers at the Francis Crick Institute, King’s College London and Complutense University of Madrid have shown that γδ T cells use adaptive immune receptors to drive rapid, innate-like responses to tissue stress, inflammation and cancer. Researchers have long divided the immune system into two broad arms: innate… Read More
In obese subjects at elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader (MGD), was shown to normalise multiple atherosclerotic cardiovascular disease (ASCVD) pathogenic drivers. Monte Rosa Therapeutics announced the finding along with other positive data from GFORCE-1, a Phase I study evaluating MRT-8102, which… Read More
A new eBook titled ‘Accelerating drug discovery with rational design’ is now available exclusively to DDW readers from Thermo Fisher Scientific. The eBook explores real-world examples demonstrating how high-resolution structural insights can inform earlier decisions, illuminate mechanisms of action, and help reduce the time, cost, and risk associated with advancing… Read More
This digital summit, hosted by DDW and supported by Sino Biological, explores the advances and challenges taking place within the field of immuno-oncology. It will take place on Wednesday, October 21, 2026 at 7am PDT / 10am EDT / 3pm BST / 4pm CEST. Featuring expert presentations and a panel… Read More
News round-up for 28 September – 2 October 2026 by Megan Thomas, Content Team at DDW. This week’s news roundup covers the upcoming the Drug Discovery Innovators & Investors Conference in London, as well as global updates on cancer research. The top stories: In-person… Read More
Numab Therapeutics has appointed Dr Rajesh Chopra as Chief Scientific Officer, who brings nearly four decades of experience across oncology, immunology, translational medicine, and drug development. Dr Chopra joined Numab from Prologue Medicines, where he served as Chief Scientific Officer, and previously was a Venture Partner at… Read More
Results of an investigators’ Phase II clinical trial in vitamin C have been published by Wiley online in Cancer, a peer-reviewed journal of the American Cancer Society. Vitamin C boosts the activity of cellular proteins called TET enzymes that help control which genes are turned on or off. Because decreased… Read More
Connect Biopharma has announced topline results from its global Phase II study evaluating rademikibart, a potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody. The treatment was assessed as an add-on treatment for acute exacerbations in adult participants with chronic obstructive pulmonary disease (COPD) and type 2 inflammation. … Read More
